<DOC>
	<DOCNO>NCT00980603</DOCNO>
	<brief_summary>The purpose study assess efficacy safety docetaxel alone , docetaxel plus cisplatin , docetaxel plus S-1 patient metastatic gastric cancer fail 1st line chemotherapy cisplatin plus S-1 capecitabine</brief_summary>
	<brief_title>Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 Second-line Chemotherapy Metastatic Gastric Cancer</brief_title>
	<detailed_description>To date , commonly use first-line chemotherapy base fluorouracil and/or cisplatin patient metastatic gastric cancer . Unfortunately , considerable proportion patient metastatic gastric cancer respond first-line chemotherapy patient respond eventually experience disease progression . In second-line treatment , however , standard therapy less clearly define . Meanwhile , regard re-challenge previous fail drug combination newly introduce chemotherapeutic agent , data . Increased expression activity thymidylate synthase , inhibited fluoropyrimidine , regard main reason development clinical resistance fluoropyrimidine . Since cotreatment docetaxel 5-fluorouracil decrease activity expression thymidylate synthase dihydropyrimidine dehydrogenase ( 5-fluorouracil degradation enzyme ) , increase expression orotate phosphoribosyl transferase , addition docetaxel S-1 may recover sensitivity S-1 patient previously resistant S-1 . Several report find MDR-1 MRP-1 related cisplatin-resistance ; cisplatin induces overexpression MRP-1 , reduce intracellular cisplatin accumulation . Since docetaxel suppress cisplatin-induced MRP-1 upregulation , addition docetaxel cisplatin may recover sensitivity cisplatin patient previously resistant cisplatin . Based synergism mechanism , speculate cotreatment docetaxel cisplatin S-1 good anti-tumor activity docetaxel alone patient resistant cisplatin S-1 .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologically confirm gastric adenocarcinoma metastatic disease Age ≥18 year Eastern Cooperative Oncology Group performance status 02 At least one measurable lesion define RECIST Only one prior chemotherapy contain S1 capecitabine cisplatin metastatic gastric cancer document progression disease occur chemotherapy within 6 month completion chemotherapy Adequate major organ function : ANC ≥1,500/mm3 , Platelet ≥100,000/mm3 , serum bilirubin ≤1.5 x upper limit normal ( ULN ) , AST/ALT ≤2.5 x ULN ( ≤5 x ULN liver metastasis present ) , creatinine clearance ≥50 ml/min use calculation formula 24 hour urine collection Patients sign write informed consent study entry Prior taxane treatment Major surgery radiotherapy le 4 week prior entry NCI CTCAE ( version 3.0 ) adverse event ≥grade 2 except alopecia , fatigue , weight loss Lack physical integrity upper gastrointestinal tract malabsorption syndrome , inability take oral medication Patients active gastrointestinal bleeding Inadequate cardiovascular function Serious concurrent infection nonmalignant illness uncontrolled whose control may jeopardize complication study therapy Other malignancy within past 3 year except adequately treat nonmelanomatous skin cancer , carcinoma situ cervix , situ prostate cancer Gleason≤7 Psychiatric disorder would preclude compliance Patients receive concomitant treatment drug interact S1 flucytosine , phenytoin , allopurinol Female patient pregnant breast feed adult reproductive potential employ effective method birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>docetaxel</keyword>
	<keyword>cisplatin</keyword>
	<keyword>S-1</keyword>
</DOC>